文献速递脊柱脊髓外科

与黄韧带肥厚相关的生物标志物:文献系统综述

Biomarkers related to hypertrophy of the ligamentum flavum: a systematic review of the literature.
PubMed 文献 · J Neurosurg Spine · 2024-04-12

该系统综述检索PubMed、Embase、Web of Science和Cochrane Library,纳入26篇评估黄韧带肥厚相关生物标志物的原始全文研究,研究开展跨越22年。最常报告的标志物为I型和III型胶原(n=10)、转化生长因子β(TGF-β)(n=8)和白细胞介素6(IL-6)(n=6)。TGF-β、IL-6及I型和III型胶原与黄韧带肥厚发生持续相关,但因研究异质性,发病机制仍不明确,需进一步研究。

要点

  • 最常研究的黄韧带肥厚生物标志物为I型和III型胶原(n=10)、TGF-β(n=8)和IL-6(n=6)。
  • 机械牵张力、TIMP-2诱导和TGF-β与I型和III型胶原增加相关。
  • 微小RNA-21及瘦素通过NF-κB通路增加IL-6表达。

核心结论

  • TGF-β、IL-6及I型和III型胶原等生物标志物与黄韧带肥厚的发生持续相关。
  • 由于研究、患者人群及分子水平研究的异质性,黄韧带肥厚的发病机制仍不明确。
  • 需进一步研究以更好地描述黄韧带肥厚的发病机制,并更全面理解这些生物标志物如何有助于黄韧带肥厚的诊断和治疗。

研究设计与样本

  • 系统综述,检索PubMed、Embase、Web of Science和Cochrane Library,检索词为黄韧带或黄韧带、生物标志物和肥厚的组合。
  • 记录数据包括研究设计、人口学特征(各性别患者数和平均年龄)、研究时段、开展国家、生物标志物及所用诊断方法。
  • 采用纽卡斯尔-渥太华量表评估病例对照研究的偏倚风险。
  • 共识别39项研究,筛选后纳入26篇评估一种或多种黄韧带肥厚相关生物标志物的原始全文文章。
  • 纳入研究开展时间跨越22年。

主要发现

  • 最常研究的生物标志物按报告频率依次为I型和III型胶原(n=10)、转化生长因子β(TGF-β)(n=8)和白细胞介素6(IL-6)(n=6)。
  • 机械牵张力、组织金属蛋白酶抑制剂2(TIMP-2)诱导和TGF-β与I型和III型胶原数量增加相关。
  • 微小RNA-21以及瘦素通过核因子κB(NF-κB)通路增加IL-6表达。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 由于研究、患者人群及分子水平研究的异质性,黄韧带肥厚的发病机制仍不明确。
  • 需进一步研究以更好地描述黄韧带肥厚的发病机制并更全面理解这些生物标志物的诊断和治疗价值。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Spinal stenosis is one of the most common spinal disorders in the elderly. Hypertrophy of the ligamentum flavum (HLF) can contribute to spinal stenosis. The current literature suggests that various biomarkers may play important roles in the pathogenesis of HLF. However, the connection between these biomarkers and the development of HLF is still not well understood. This systematic review aims to explore the current literature on biomarkers related to the development of HLF. METHODS: A literature search was conducted using PubMed, Embase, Web of Science, and Cochrane Library. The search strategy looked for the titles, abstracts, and keywords of studies that contained a combination of the following phrases: "ligamentum flavum OR yellow ligament," "biomarkers," and "hypertrophy." Recorded data included study design, demographic characteristics (number of patients of each gender and mean age), study period, country where the study was conducted, biomarkers, and diagnostic modalities used. Risk of bias was assessed using the Newcastle-Ottawa Scale for case-control studies. RESULTS: The authors identified 39 studies. After screening, 26 full-text original articles assessing one or more biomarkers related to HLF were included. The included studies were conducted over a 22-year period. The most popular biomarkers studied, in order of frequency reported, were collagen types I and III (n = 10), transforming growth factor β (TGF-β) (n = 8), and interleukin (IL)-6 (n = 6). The authors found that mechanical stretching forces, tissue inhibitor of metalloproteinases 2 (TIMP-2) induction, and TGF-β were associated with increased amounts of collagen I and III. IL-6 expression was increased by microRNA-21, as well as by leptin, through the nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) pathway. CONCLUSIONS: Biomarkers such as TGF-β, IL-6, and collagen I and III have been consistently correlated with the development of HLF. However, the pathogenesis of HLF remains unclear due to the heterogeneity of the studies, patient populations, and research at the molecular level. Further studies are necessary to better characterize the pathogenesis of HLF and provide a more comprehensive understanding of how these biomarkers may aid in the diagnosis and treatment of HLF.

来源:J Neurosurg Spine,查看原文。版权归原作者所有。

引用

  1. Mualem W, Liu J, Balu A, et al. Biomarkers related to hypertrophy of the ligamentum flavum: a systematic review of the literature. J Neurosurg Spine. 2024. PMID: 38608299. doi:10.3171/2024.2.SPINE23991

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。